Clinical trials: Opioid Dependence
Opioid-Related Disorders
Evaluation of Pharmacy Students' Perception of Opioid / Opiate Dependence
The pharmacist in his professional activity may have to manage opioid dependent patients. This professional activity will result in the provision of opioid substitution treatment (OST), single-use syringes, harm reduction kits…
- Trial name
- STUD_TOX (NCT03859778)
- Testing
- survey
- Where
- France
- Volunteers
- 2,034 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Opioid Dependence
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
The investigators will randomize 50 opioid-dependent participants who have initially failed outpatient induction onto XR-NTX; participants will receive buprenorphine/naloxone on a weekly basis for 30 days.
- Trial name
- NCT02294253
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Alcohol Dependence
A Study of Brain Receptor Occupancy in Healthy Subjects
To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
- Trial name
- NCT01232439
- Testing
- opioid receptor kappa antagonist
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cocaine Dependence, Opioid Dependence
FMRI of Stress and Addictive Disorders
The purpose of this study is to explore whether frontal brain activation in response to stress varies as a function of the presence or extent of early trauma and whether or not this effect is greater in women compared to men.
- Conditions
- Cocaine Dependence, Opioid Dependence, Alcoholism, Pathological Gamblers
- Trial name
- NCT01558973
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Yale University
Opioid Dependence, Opioid Related Disorders
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
This is a randomized, 4-sequence, 2-period, double-blind, placebo controlled study in male and female subjects with an American Psychiatric Association Diagnostic and Statistical Manual DSM-IV-TR diagnosis of cocaine abuse.
- Conditions
- Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
- Trial name
- RBP-8000 (NCT01846481)
- Testing
- RBP-8000 100 mg, Cocaine, RBP-8000 200 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Opioid Dependence
INDV-2000 First in Human
This study is a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD) of INDV-2000. After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction…
- Trial name
- NCT04413552
- Testing
- INDV-2000
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Heroin Dependence
Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts
Opioid abuse is a complex problem, which not only impacts on addicts' physical and psychological health individually, but also threats the society.
- Trial name
- NCT01668706
- Where
- 5 sites in Taiwan
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Smoking Cessation
A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients
The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol…
- Trial name
- NCT02665208
- Testing
- Treatment As Usual (TAU), Nicotine Replacement Therapies, Text Message Intervention (TMI)
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Opioid-Related Disorders
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine.
- Trial name
- NCT00134914
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Pain, Chronic, Opioid Dependence
The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients
This is a research study to evaluate the effectiveness of daily supplementation with Root.Health, a plant-based dietary supplement, on reducing levels of 11 abnormal urine biomarkers associated with chronic pain.
- Conditions
- Pain, Chronic, Opioid Dependence, Opioid Use, Inflammation Chronic
- Trial name
- NCT05896878
- Testing
- Root.Health Dietary Supplement
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Hudson Medical
Opioid Dependence
XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs.
- Trial name
- NCT03604159
- Testing
- Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Opioid Abuse (Disorder), Opioid Analgesia
Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity
The goal of this clinical trial is to evaluate strategies for optimizing postoperative multimodal pain regimens and reducing opioid dependency in patients undergoing upper extremity surgery.
- Conditions
- Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
- Trial name
- NCT07750639
- Testing
- Naproxen, Acetaminophen, oxycodone
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- AdventHealth
Anger, Opioid Use
Chronic Pain, Opioids, and Anger Treatment
The current US opioid epidemic is a pressing public health concern. Links between opioid misuse and mortality are well-known; nearly 70% of all drug overdose deaths in 2017 were attributable to opioids.
- Conditions
- Anger, Opioid Use, Chronic Pain
- Trial name
- NCT04438746
- Testing
- Emotion discussion, Cognitive Behavioral Affective Therapy
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- The University of Texas at San Antonio
Opioid Dependence, Substance-Related Disorders
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.
- Trial name
- NCT00015340
- Testing
- Buprenorphine/naloxone
- Where
- 5 sites in United States
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Genetic Underpinning of Substance Abuse, Polymorphism-genetic
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
Background: Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction.
- Conditions
- Genetic Underpinning of Substance Abuse, Polymorphism-genetic, Drug Abuse/Dependence, Opiod-Related Disorders
- Trial name
- NCT02225184
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)